Publications by authors named "Jacques Creemers"
Rationale: Advance care planning (ACP) is uncommon in patients with chronic obstructive pulmonary disease (COPD).
Objectives: To assess whether a nurse-led ACP-intervention can improve quality of patient-physician end-of-life care communication in patients with COPD. Furthermore, the influence of an ACP-intervention on symptoms of anxiety and depression in patients and loved ones was studied.
Background: Frequent exacerbations induce a high burden to Chronic Obstructive Pulmonary Disease (COPD). We investigated the course of exacerbations in the published COSMIC study that investigated the effects of 1-year withdrawal of fluticasone after a 3-month run-in treatment period with salmeterol/fluticasone in patients with COPD.
Methods: In 373 patients, we evaluated diary cards for symptoms, Peak Expiratory Flow (PEF), and salbutamol use and assessed their course during exacerbations.
ABSTRACT Aclidinium bromide is a novel, long-acting, inhaled muscarinic antagonist in development for the treatment of chronic obstructive pulmonary disease (COPD). The aim of this study was to assess the rate of onset of bronchodilation with aclidinium compared with placebo and tiotropium. This was a double-blind, double-dummy, multicenter, crossover study in COPD patients with a post-bronchodilator forced expiratory volume in 1 second (FEV(1)) ≥30% and <60% predicted.
View Article and Find Full Text PDFArticle Synopsis
- Dry powder devices are seldom used in ER settings for acute bronchoconstriction due to concerns about their effectiveness.
- This study compared the efficacy of two inhalers (Turbuhaler vs. pMDI+S) delivering formoterol for patients experiencing severe dyspnoea from COPD exacerbations.
- Results indicated that both inhalers produced nearly identical improvements in lung function (FEV(1)) and shortness of breath scores, confirming that Turbuhaler is as effective as the pMDI+S in treating acute bronchoconstriction in the ER.
Article Synopsis
- The study aimed to evaluate the impact of switching asthma patients from a conventional treatment (CFC-BDP) to a newer option (HFA-BDP) on their health-related quality of life over 12 months.
- In a trial with 473 participants across multiple countries, those on HFA-BDP experienced significant improvements in asthma-specific quality of life compared to those continuing with CFC-BDP, as measured by the Asthma Quality of Life Questionnaire (AQLQ).
- Despite the benefits in quality of life, there were no significant differences between the two treatment groups in terms of lung function, asthma symptoms, or the use of rescue medication, indicating that both treatments were similarly effective in clinical terms.
Objectives: To compare the onset and magnitude of bronchodilation after dry powder inhalations of formoterol fumarate (Foradil Aerolizer) versus salmeterol xinofoate (Serevent Diskus) with respect to normalized (*) forced expiratory volume in 1 s area under the curve 0 to 1 h after inhalation (FEV1 AUC*0-1 h).
Design: A double-blind, double-dummy, multicentre, randomized, placebo controlled, single-dose, five-period crossover study.
Setting: Five centres in four countries - one centre each in France, Greece and Italy, and two centres in the Netherlands.